

Ref: EPL/CS/SE/0024/2026

Date: March 24, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Script Symbol: EMCURE	BSE Limited P J Towers, Dalal Street, Mumbai - 400 001 Scrip Code/Symbol: 544210/ EMCURE
---	---

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015 - Proceedings of Postal Ballot

Pursuant to Regulation 30 read with clause 13 of Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015, we are submitting herewith proceedings of the postal ballot and the certified true copy of the special resolutions passed by the Members of the Company on Friday, March 20, 2026, through the said postal ballot.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Amruta Yangelwar
Company Secretary & Compliance Officer
Membership Number: A25687

Encl.: As above

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

PROCEEDINGS OF THE POSTAL BALLOT AND CERTIFIED TRUE COPY OF THE RESOLUTIONS PASSED BY THE MEMBERS OF EMCURE PHARMACEUTICALS LIMITED ("THE COMPANY") ON FRIDAY, MARCH 20, 2026 THROUGH POSTAL BALLOT:

In compliance with Sections 108 and 110 of the Companies Act, 2013 ("**the Act**") read with Rule 20 and Rule 22 of the Companies (Management and Administration) Rules, 2014 ("**the Rules**") and other applicable provisions of the Act, if any, read with its Rules, as amended from time to time, the guidelines prescribed by the Ministry of Corporate Affairs ("**MCA**") for holding general meetings/ conducting postal ballot process through e-voting vide General Circulars issued by MCA, the latest being No. 03/2025 dated September 22, 2025, Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**") read with Securities and Exchange Board of India ("**SEBI**") Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 ("**SEBI Master Circular**"), Secretarial Standard on General Meetings ("**SS-2**") issued by the Institute of Company Secretaries of India and other applicable laws, rules and regulations (*including any statutory modification(s) or re-enactment(s) thereof for the time being in force*), approval of the Members of the Company was sought by way of Postal Ballot for:

1. Re-appointment of Mr. Vijay Keshav Gokhale (DIN: 09134089) as an Independent Director of the Company;
2. Re-appointment of Dr. Vidya Rajiv Yeravdekar (DIN: 02183179) as an Independent Director of the Company; and
3. Re-appointment of Dr. Shailesh Kripalu Ayyangar (DIN: 00268076) as an Independent Director of the Company.

The Notice of Postal Ballot dated February 17, 2026, comprising resolutions proposed for approval of the Members and the explanatory statement thereto and reasons thereof, was sent to the Members only through email on Tuesday, February 17, 2026, whose email addresses were registered with the Depositories (in case of Members holding shares in Demat form) and whose names appeared in the Register of Members/ List of Beneficial Owners as received from National Securities Depository Limited ("**NSDL**") and Central Depository Services (India) Limited ("**CDSL**"), as on Friday, February 13, 2026 ("**cut-off date**").

In compliance with relevant circulars, the Postal Ballot was conducted, by electronic means through the remote e-voting facility and accordingly the Members were required to communicate their assent or dissent through the remote e-voting facility only.

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Further, the Company issued public notice by way of advertisement in the newspapers viz: "Financial Express"- all editions (English) and "Loksatta"- Pune edition (Marathi) on Wednesday, February 18, 2026, in respect of Notice of Postal Ballot providing information relating to manner and duration of remote e-voting, manner in which shareholders whose emails addresses are not registered may cast their vote through remote e-voting and manner of registering email address and other required information. The copy of the same was submitted to BSE Limited and National Stock Exchange of India Limited and was also placed on the website of the Company.

The Company provided the remote e-voting facility to enable the Members to cast their vote in electronic mode through the Registrar and Share Transfer Agent of the Company i.e., MUFG Intime India Private Limited (*Formerly known as Link Intime India Private Limited*). Further, pursuant to SEBI Master Circular, all the individual shareholders holding shares in demat mode were provided with the facility to cast their vote through the remote e-voting by way of single login credential through their demat accounts / websites of Depositories / Depository Participants (DPs).

The remote e-voting was enabled on Thursday, February 19, 2026 at 9:00 a.m. (IST) and was disabled on Friday, March 20, 2026 at 5:00 p.m. (IST). During this period, Members of the Company, holding shares, as on the cut-off date, were able to cast their votes through remote e-voting on the resolution set out in the Notice of Postal Ballot.

Pursuant to Rule 22(5) of the Companies (Management and Administration) Rules, 2014, Ms. Ashwini Inamdar (Membership No. FCS 9409, CP No. 11226) Partner, M/s. Mehta & Mehta, Practicing Company Secretaries, Mumbai, has been appointed as the Scrutinizer by the Board of Directors for conducting the Postal Ballot voting process in a fair and transparent manner.

Upon conclusion of the remote e-voting period, the Scrutinizer carried out the scrutiny of votes cast through the remote e-voting on the item of business(es) as set out in the Postal Ballot Notice and submitted her Report dated Monday, March 23, 2026. The Scrutinizer in her report, *inter-alia*, confirmed that the Postal Ballot voting process was conducted in a fair and transparent manner. As per the Scrutinizer's report, all the resolutions have been passed by the Members with requisite majority.

The Board had severally authorized the Chairman or Managing Director or the Company Secretary and Compliance Officer of the Company, to receive the Scrutiniser's Report and declare the voting results.

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

SPECIAL RESOLUTIONS PASSED BY WAY OF POSTAL BALLOT THROUGH REMOTE E-VOTING BY THE MEMBERS OF EMCURE PHARMACEUTICALS LIMITED ON FRIDAY, MARCH 20, 2026.

1. RE-APPOINTMENT OF MR. VIJAY KESHAV GOKHALE (DIN: 09134089) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:

“RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (**“the Act”**) (*including any statutory modifications or re-enactments thereof for the time being in force*) read with the Companies (Appointment and Qualification of Directors) Rules, 2014, and pursuant to Regulation 17 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (**“SEBI Listing Regulations”**), as recommended by the Nomination & Remuneration Committee (**“NRC”**) and the Board of Directors, Mr. Vijay Keshav Gokhale (DIN: 09134089 and IDDB Registration Number : IDDB-NR-202104-035839), who was appointed as an Independent Director of the Company upto April 15, 2026, and is eligible for re-appointment as an Independent Director pursuant to the provisions of the Act and SEBI Listing Regulations and who has submitted a declaration that he meets the criteria of Independence as per Section 149(6) of the Act read with the Rules framed thereunder and Regulation 16(1)(b) of the SEBI Listing Regulations and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing his candidature for the re-appointment for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of 5 (five) consecutive years with effect from April 16, 2026.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 197 and other applicable provisions of the Act read with the Rules made thereunder (*including any statutory modification(s) or re-enactment thereof for the time being in force*), Mr. Vijay Keshav Gokhale shall be paid such fees, remuneration and/ or profit related commission as the Board / NRC may approve from time to time and subject to such limits, prescribed or as may be prescribed.

RESOLVED FURTHER THAT the Board, be and is hereby authorised to do all such acts, deeds and things as may be considered necessary, desirable and expedient for the purpose of giving effect to this resolution and for matters connected therewith or incidental thereto.”

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

2. **RE-APPOINTMENT OF DR. VIDYA RAJIV YERAVDEKAR (DIN: 02183179) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:**

“RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (“the Act”) (including any statutory modifications or re-enactments thereof for the time being in force) read with the Companies (Appointment and Qualification of Directors) Rules, 2014, and pursuant to Regulation 17 and other applicable regulations, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“SEBI Listing Regulations”), as recommended by the Nomination & Remuneration Committee (“NRC”) and the Board of Directors, Dr. Vidya Rajiv Yeravdekar (DIN: 02183179 and IDDB Registration Number : IDDB-DI-202104-036006), who was appointed as an Independent Director of the Company upto April 15, 2026 and is eligible for re-appointment as an Independent Director pursuant to the provisions of the Act and SEBI Listing Regulations and who has submitted a declaration that she meets the criteria of Independence as per Section 149(6) of the Act read with the Rules framed thereunder and Regulation 16(1)(b) of the SEBI Listing Regulations and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing her candidature for the re-appointment for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of 3 (three) consecutive years with effect from April 16, 2026.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 197 and other applicable provisions of the Act read with the Rules made thereunder (including any statutory modification(s) or re-enactment thereof for the time being in force), Dr. Vidya Rajiv Yeravdekar shall be paid such fees, remuneration and/ or profit related commission as the Board / NRC may approve from time to time and subject to such limits, prescribed or as may be prescribed.

RESOLVED FURTHER THAT the Board, be and is hereby authorised to do all such acts, deeds and things as may be considered necessary, desirable and expedient for the purpose of giving effect to this resolution and for matters connected therewith or incidental thereto.”

3. **RE-APPOINTMENT OF DR. SHAILESH KRIPALU AYYANGAR (DIN: 00268076) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:**

“RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions of the Companies Act, 2013 (“the Act”) (including any statutory modifications or re-enactments thereof for the time being in force) read with the Companies (Appointment and Qualification of Directors) Rules, 2014, and pursuant to Regulation 17 and other applicable regulations, if any, of the Securities and Exchange Board

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 Fax No.: +91 20 3507 0060

E-mail: corporate@emcure.com Website: www.emcure.com CIN: L24231PN1981PLC024251

of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“**SEBI Listing Regulations**”), as recommended by the Nomination & Remuneration Committee (“NRC”) and the Board of Directors, Dr. Shailesh Kripalu Ayyangar (DIN: 00268076 and IDDB Registration Number : IDDB-DI-202007-029759), who was appointed as an Independent Director of the Company upto June 01, 2026 and is eligible for re-appointment as an Independent Director pursuant to the provisions of the Act and SEBI Listing Regulations and who has submitted a declaration that he meets the criteria of Independence as per Section 149(6) of the Act read with the Rules framed thereunder and Regulation 16(1)(b) of the SEBI Listing Regulations and in respect of whom the Company has received a notice in writing from a Member under Section 160 of the Act proposing his candidature for the re-appointment for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation, to hold office for a second term of 5 (five) consecutive years with effect from June 02, 2026.

RESOLVED FURTHER THAT pursuant to the provisions of Sections 149, 197 and other applicable provisions of the Act read with the Rules made thereunder (*including any statutory modification(s) or re-enactment thereof for the time being in force*), Dr. Shailesh Kripalu Ayyangar shall be paid such fees, remuneration and/ or profit related commission as the Board / NRC may approve from time to time and subject to such limits, prescribed or as may be prescribed.

RESOLVED FURTHER THAT pursuant to Regulation 17(1A) of the SEBI Listing Regulations (*including any statutory amendments, modifications(s) or re-enactment(s) thereof for the time being in force*), approval of the Members be and is hereby accorded for continuation of directorship of Dr. Ayyangar as an Independent Director of the Company, post attaining the age of 75 years.

RESOLVED FURTHER THAT the Board, be and is hereby authorised to do all such acts, deeds and things as may be considered necessary, desirable and expedient for the purpose of giving effect to this resolution and for matters connected therewith or incidental thereto.”

For, **Emcure Pharmaceuticals Limited**

Amruta Yangalwar
Company Secretary & Compliance Officer
Membership Number: A25687

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251